ReviewJACC. CardioOncology2022
Cardiovascular Disease in Myeloproliferative Neoplasms:
Review in JACC. CardioOncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 73 citations in OpenAlex.
- Telehealth-Delivered Dietary Counseling in Myeloproliferative Neoplasms: A Randomized Feasibility Study.Nutrients · 2026Trial
- Review
- Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Patients with Organ Dysfunction.Oncology · 2026Review
- Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms.International journal of hematology · 2026Article
- Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.Cardio-oncology (London, England) · 2026Review
- Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation.ACR open rheumatology · 2026Review
- Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms.Blood advances · 2026Article
- Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes.Blood advances · 2026Article
- Impact of echocardiographic hemodynamics on outcomes among patients with polycythemia vera or essential thrombocythemia.Cardio-oncology (London, England) · 2026Article
- Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.Cardio-oncology (London, England) · 2026Article
- Exploring the Association Between Pulmonary Hypertension and Cancer: A Systematic Review and Meta-Analysis.Biomedicines · 2026Review
- Sotatercept for the Treatment of Myeloproliferative Neoplasm-Associated Group 5 Pulmonary Hypertension.JACC. CardioOncology · 2026Article
- Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.Cardio-oncology (London, England) · 2026Article
- Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms.Blood advances · 2026Article
- Primary and Secondary Prevention of Ischemic Stroke in Elderly Patients with Cardiovascular Disease: The Role of Frailty and Care Pathways.Neurology international · 2026Review
- Cardiac mass in a patient with HIV infection: A case report and literature review.Experimental and therapeutic medicine · 2026Article
- Clonal hematopoiesis of indeterminate potential and cardiovascular disease: mechanistic insights, clinical implications, and the dawn of precision cardio-hematology.Frontiers in cardiovascular medicine · 2026Review
- Molecular basis of coronary artery disease-malignancy comorbidity: inflammation, immunometabolism, thrombosis, and cardio-oncology translation.Frontiers in immunology · 2026Review
- Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database.Journal of thrombosis and thrombolysis · 2025Article
- Recent insights into the pathophysiology and implications for surgery in atherosclerosis.Journal of cardiothoracic surgery · 2025Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a recently recognized age-related promoter of cardiovascular disease, to frank hematologic malignancy. Beyond thrombosis, patients with myeloproliferative neoplasms can develop other cardiovascular conditions, including heart failure and pulmonary hypertension. The authors review the pathophysiologic mechanisms of cardiovascular complications of myeloproliferative neoplasms, which involve inflammation, prothrombotic and profibrotic factors (including transforming growth factor-beta and lysyl oxidase), and abnormal function of circulating clones of mutated leukocytes and platelets from affected individuals. Anti-inflammatory therapies may provide cardiovascular benefit in patients with myeloproliferative neoplasms, a hypothesis that requires rigorous evaluation in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.